EP3735975
ERTUGLIFLOZIN FOR USE IN TREATING HEART FAILURE IN PATIENTS WITH DIABETES
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
6.3.2017EP published:
3.12.2025EP application number:
20177822.2
EPO information:
European Patent Register
Max expiry date:
5.3.2037
Title in English:
ERTUGLIFLOZIN FOR USE IN TREATING HEART FAILURE IN PATIENTS WITH DIABETESLanguage of the patent:
English
Timeline
Today
6.3.2017EP application
3.12.2025EP Publication
Owner
Name:
Merck Sharp & Dohme LLCAddress:
126 East Lincoln Avenue, Rahway, New Jersey 07065, US
Name:
Pfizer Inc.Address:
235 East 42nd Street, New York, NY 10017, US
Inventor
Name:
LAURING, BrettAddress:
Rahway, New Jersey 07065-0907, US
Name:
ENGEL, Samuel, S.Address:
Rahway, New Jersey 07065-0907, US
Name:
RUSNAK, James, M.Address:
New York, New York 10017, US
Name:
TERRA, Steven, G.Address:
New York, New York 10017, US
Priority
Number:
201662306907 PDate:
11.3.2016Country:
US
Classification
Categories:
A61K 31/7048, A61K 31/155, A61K 31/4985, A61K 31/5513, A61K 31/381, A61P 9/10, A61P 9/04, A61K 31/357